←
Dr Amar Puttanna 🎸15,908 posts
Dr Amar Puttanna 🎸 avatar

Dr Amar Puttanna 🎸

@AmarPut

EPCA winner|QiC award DIADEM| @BrJCardiol|Diabetes Consultant-frailty, ageing, dementia, oral health, sustainability, cardiovascular| @GoggleDocs|tweets my own

◷ Joined February 2017▧ 1,717 Photos and videos
Professor Kamlesh Khunti avatar
⟳ Dr Amar Puttanna 🎸 retweeted
Professor Kamlesh Khunti@kamleshkhunti·Oct 14

🧓 Can GLP-1 RAs help preserve function in people with diabetes? In 73,592 propensity-matched pairs, GLP-1 RA initiation vs DPP-4 inhibitors was associated with: 📉 Less frailty progression 🚶 13% lower fall rate (IRR 0.87, 95% CI 0.84–0.91) ⚠️ Associations were weaker in severe baseline frailty. Real-world evidence, not proof of causality. #Diabetes #Frailty #GLP1RA #Geriatrics dom-pubs.onlinelibrary.wiley… @AskDrShashank

Post attachment
Professor Kamlesh Khunti avatar
⟳ Dr Amar Puttanna 🎸 retweeted
Professor Kamlesh Khunti@kamleshkhunti·Oct 13

GLP-1/GIP RAs vs finerenone in T2D + CKD: What does real-world evidence show? In 4,554 propensity-matched patients, GLP-1/GIP RAs were associated with a 29% lower relative hazard of kidney disease progression vs finerenone over 2.5 years (HR 0.71, 95% CI 0.55–0.91). 🔎 However, no clear difference in absolute risk or chronic eGFR slope emerged. #Nephrology #Diabetes #CKD #GLP1RA @AskDrShashank dom-pubs.onlinelibrary.wiley… GLP vs finerenone

Post attachment
GoggleDocs avatar
⟳ Dr Amar Puttanna 🎸 retweeted
GoggleDocs@GoggleDocs·Sep 29

🚨Retatrutide TRIUMPH-1 (NEJM) 80 wk weight: ⤵️25% on 12 mg vs -3.9% placebo. ⤵️28.3% headline = efficacy estimand. 👉9 vs 12 mg near identical; only 54% still on 12 mg at wk 80 ⚠️⚡️Dysaesthesia, hypotension, MACE 9 v 1 (small n) Treat to target, not max dose❓ 🔗 nejm.org/doi/full/10.1056/NE…

Post attachment
NEJM avatar
⟳ Dr Amar Puttanna 🎸 retweeted
NEJM@NEJM·Sep 29

In the phase 3 TRIUMPH-1 trial involving patients with obesity, retatrutide, a triple hormone receptor agonist, resulted in substantial weight reduction and a decrease in knee osteoarthritis pain and obstructive sleep apnea events. Full trial results: nej.md/4ycgSHz

Post attachment
Partha S Kar 🇮🇳🇬🇧🏏🎥 avatar
⟳ Dr Amar Puttanna 🎸 retweeted
Partha S Kar 🇮🇳🇬🇧🏏🎥@parthaskar·Sep 29

If you are at @EASDnews and fancy coming to a “different” way of doing a session? Come along Sharing a stage with those with lived experience - what’s the point otherwise anyway #T1Diabetes and #T2Diabetes And some provocative discussions on whether everyone should have a CGM in tight health budgets Whether hypos are really THAT big an issue Whether AI is just about tech-bros jumping onto a fad in diabetes care And whether pineapple belongs on a pizza. And oh it’s not a typical stage either Come along for some fun- if you can. #EASD2026 #Milan

Post attachment
Dr Amar Puttanna 🎸 avatar
Dr Amar Puttanna 🎸@AmarPut·Sep 29

Great to share the stage with colleagues and friends @EASDnews #EASD2026 Discussing bringing data to the masses: 👉🏽how we shape conversations 👉🏽build interest 👉🏽maintain integrity 👉🏽 enjoy ourselves 🥳 Thank you @novonordisk for the opportunity and the interest!

Post attachmentPost attachment
0:05
Dr Amar Puttanna 🎸 avatar
Dr Amar Puttanna 🎸@AmarPut·Sep 17

❗️Interesting to see the confluence of specialty areas❗️ Thank you @PCDSUK for the invite to talk! A forward thinking meeting! (Loving the purple theme 😁) Fascinating to hear dermatology interest & create plans going forwards -another specialty to bring to the metabolic mix!

Post attachment
GoggleDocs avatar
⟳ Dr Amar Puttanna 🎸 retweeted
GoggleDocs@GoggleDocs·Aug 29

#ESCcongress2025 💊 STAREE in NEJM: atorvastatin 40mg vs placebo, 9,971 adults aged 70+, 5.9 yrs 📉 Major CV events HR 0.70 ✅ NNT 37 ⚖️ Disability-free survival HR 0.94 (0.84–1.05) ❌ 📊 CV death HR 1.00 Fewer heart attacks. Not a longer or more independent life

Post attachment